Trail death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma


SANLIOGLU A. D., KORCUM A. F., Pestereli E., Erdogan G., Karaveli S., SAVAS B., ...More

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.69, no.3, pp.716-723, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 3
  • Publication Date: 2007
  • Doi Number: 10.1016/j.ijrobp.2007.03.057
  • Journal Name: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.716-723
  • Keywords: breast cancer, TRAIL, DR4, apoptosis, COOPERATIVE-ONCOLOGY-GROUP, AMERICAN-JOINT-COMMITTEE, PROGNOSTIC-FACTORS, RADIATION-THERAPY, FAS LIGAND, STAGE-I, CELLS, APOPTOSIS, RESISTANCE, SURVIVAL
  • Akdeniz University Affiliated: Yes

Abstract

Purpose: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) selectively induces apoptosis in cancer cells but not in normal cells, and a number of clinical trials have recently been initiated to test the safety and antitumoral potential of TRAIL in cancer patients. Four different receptors have been identified to interact with TRAIL: two are death-inducing receptors (TRAIL-R1 [DR4] and TRAIL-R2 [DR5]), whereas the other two (TRAIL-R3 [DcR1] and TRAIL-R4 [DcR2]) do not induce death upon ligation and are believed to counteract TRAIL-induced cytotoxicity. Because high levels of DcR2 expression have recently been correlated with carcinogenesis in the prostate and lung, this study investigated the importance of TRAIL and TRAIL receptor expression in breast cancer patients with invasive ductal carcinoma, taking various prognostic markers into consideration.